-

12:28:28 PM

SNWV Stock News

SNWV - Sanuwave Health Inc

08/23/23 4:30 PM

OTC : SNWV

acquisitionfda approval

SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company

� SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol “SNWV”. · The combined company expects to receive

RHEA-AI

neutral

08/11/23 6:00 AM

OTC : SNWV

earnings

SANUWAVE Announces Q2 2023 Financial Results

SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: Revenue for the

RHEA-AI

negative

08/09/23 5:22 PM

OTC : SNWV

conferencesearnings

SANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial Results

via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 11, 2023, at 8:30AM (EDT) to present its Q2 2023 financial

RHEA-AI

neutral

08/01/23 7:30 AM

OTC : SNWV

SANUWAVE Signs Distribution Agreement With Pacific Medical, Inc.

Pacific Medical to bring its sales force of over 215 dedicated representatives covering seven western states to the SANUWAVE UltraMist line of directed energy wound care products. Long-term agreement to develop and expand the market for SANUWAVE “Energy First” treatments. EDEN PRAIRIE, MN, Aug.

RHEA-AI

neutral

07/31/23 7:30 AM

OTC : SNWV

management

SANUWAVE Health Appoints Industry Veteran Andrew Walko as President

SANUWAVE Health, Inc. (the

RHEA-AI

neutral

07/17/23 7:30 AM

OTC : SNWV

earnings

SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter Ended June 30, 2023

via NewMediaWire

RHEA-AI

neutral

05/24/23 9:00 AM

OTC : SNWV

management

SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer

via NewMediaWire – SANUWAVE Health, Inc. (the

RHEA-AI

neutral

05/12/23 7:30 AM

OTC : SNWV

earnings

SANUWAVE Announces Q1 2023 Financial Results

via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: Revenues increased 18% to $3.8

RHEA-AI

negative

05/11/23 7:30 AM

OTC : SNWV

SANUWAVE Will Host a Live Conference Call and Webcast May 12, 2023 at 9:00 AM to Provide a Financial and Business Update

via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call on Friday, May 12, 2023, at 9:00AM (EDT) to discuss a financial update and recent strategic

RHEA-AI

neutral

04/27/23 8:30 AM

OTC : SNWV

conferences

SANUWAVE Health to Attend the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) Conference

via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce its participation in the upcoming 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound

RHEA-AI

very positive

1 2 3 4 5 6 Next

SNWV Data

IndustrySurgical and Medical Instrument Manufacturing
Security nameSanuwave Health Inc
SectorManufacturing
Tags
- Miscellaneous
- Manufacturing
- Surgical and Medical Instrument Manufacturing

About Sanuwave Health Inc

sanuwave, inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. sanuwave's portfolio of products and product candidates activate biologic signaling and angiogenic reponses, including revascularization and microcirculation, helping to restore the body's normal healing processes and regeneration. these devices, based on pulsed acoustic cellular expression (pace™) technology, are being developed and commercialized for use in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.